Impact of Intraoperative Continuous-Infusion Versus Intermittent Dosing of Cefazolin Therapy on the Incidence of Surgical Site Infections after Coronary Artery Bypass Grafting

Pharmacotherapy

Volumn 36, Issue 2, 2016, Pages 166-173

  Shoulders, Bethany R ^a   Crow, Jessica R ^a   Davis, Stephanie L ^a   Whitman, Glenn J ^a   Gavin, Melanie ^a   Lester, Laeban ^a   Barodka, Viachaslau ^b   Dzintars, Kathryn ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiac surgery; cefazolin; continuous infusion; intraoperative antibiotics; prophylaxis; surgical site infections

Indexed keywords

CEFAZOLIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PROTOCOL COMPLIANCE; QUASI EXPERIMENTAL STUDY; RETROSPECTIVE STUDY; SEIZURE; SURGICAL INFECTION; UNIVERSITY HOSPITAL; ADVERSE EFFECTS; ANTIBIOTIC PROPHYLAXIS; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MARYLAND; MIDDLE AGED; PATHOPHYSIOLOGY; PEROPERATIVE CARE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SURGICAL WOUND INFECTION;

ACADEMIC MEDICAL CENTERS; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BALTIMORE; CEFAZOLIN; COHORT STUDIES; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURGICAL WOUND INFECTION;

EID: 84958845475     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1689     Document Type: Article

References (17)

1. Engelman R, Shahian D, Shemin R, et al., The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice. Ann Thorac Surg 2007; 83: 1569-76.
2. Sharma M, Berriel-Cass D, Baran J Jr,. Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period. Infect Control Hosp Epidemiol 2004; 25 (6): 468-71.
3. Bratzler DW, Dellinger EP, Olsen KM, et al., Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70: 195-283.
4. Allen KB, Fowler VG Jr, Gammie JS, et al., Staphylococcus aureus infections after elective cardiothoracic surgery: observations from an international randomized placebo-controlled trial of an investigational S. aureus vaccine. Open Forum Infect Dis 2014; 1 (2): ofu071.
5. Fellinger EK, Leavitt BJ, Hebert JC,. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. Ann Thorac Surg 2002; 74: 1187-90.
6. Bulyaert WA, Herregods LL, Mortier EP, Bogaert MG,. Cardiopulmonary bypass and the pharmacokinetics of drugs. Clin Pharmacokinet 1989; 17: 10-26.
7. Schaper KF, Schubert S, Dalhoff A,. Kinetics and quantification of antibacterial effects of beta lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens. Infection 2005; 33: 3-14.
8. Waltrip T, Lewis R, Young V, et al., A pilot study to determine the feasibility of continuous cefazolin infusion. Surg Infect (Larchmt) 2002; 3 (1): 5-9.
9. Adembri C, Ristori R, Chelazzi C, et al., Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. J Thorac Cardiovasc Surg 2010; 140 (2): 471-5.
10. Lu JCY, Grayson AD, Jha P, Srinivasan AK, Fabri BM,. Risk factors for sternal wound infection and mid-term survival following coronary artery bypass surgery. Eur J Cardiothorac Surg 2003; 23: 943-9.
11. Risnes I, Abdelnoor M, Almdahl SM, Svennevig JL,. Mediastinitis after coronary artery bypass grafting risk factors and long-term survival. Ann Thorac Surg 2010; 89: 1502-10.
12. Segers P, de Jong AP, Kloek JJ, Spanjaard L, de Mol BAJM,. Risk control of surgical site infection after cardiothoracic surgery. J Hosp Infect 2006; 62: 437-45.
13. Hillis LD, Smith PK, Anderson JL, et al., 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2011; 124: e652-735.
14. Kreter B, Woods M,. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992; 104 (3): 590-9.
15. Center for Disease Control and National Health Surveillance Network. Surgical Site Infection (SSI) Event. January 2014. Available from http://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf. Accessed October 8, 2014.
16. Magruder JT, Grimm JC, Dungan SP, et al., Continuous intraoperative cefazolin infusion may reduce surgical site infections during cardiac surgical procedures: a propensity-matched analysis. J Cardiothorac Vasc Anesth 2015; 29 (6): 1582-7.
17. Harris AD, Bradham DD, Baumgarten M, et al., The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis 2004; 38: 1586-91.